Compound veterinary preparation for treating poultry enteritis type colibacillosis

Abstract

The invention belongs to a composition for treating poultry enteritis type colibacillosis in veterinary medicines. The preparation consists of the following components in percentage by weight: 3.25 percent of neomycin sulfate, 0.81 percent of lactate TMP (trimethoprim lactate), 10 percent of glutamine, and 85.94 percent of auxiliary glucose, wherein neomycin sulfate, lactate TMP and glutamine are main drug components. The veterinary composition is used for treating poultry enteritis type colibacillosis. The processing process of the composition comprises the following steps: respectively crushing and screening each component, and accurately weighing according to the required proportion; mixing for 25 minutes; inspecting a semifinished product; subpackaging, packaging and inspecting the finished product. According to the usage method, the composition is drunk in a ratio of 1 percent, and four days are taken as a course of treatment. The composition has a remarkable curative effect on poultry enteritis type colibacillosis, is low in drug tolerance, safe and low-toxic, and has good popularization and application values.

Description

technical field

[0001] The invention relates to a compound veterinary drug preparation and a preparation process for treating poultry enteritis colibacillosis. Background technique

[0002] Colibacillosis is one of the most common diseases in poultry farming, and enteritis colibacillosis is also one of the most serious diseases. In veterinary clinics, after poultry is infected with enteritis colibacillosis, it often manifests as diarrhea, loss of appetite, rough feathers, indigestion of feed, slow growth, gradual increase in elimination rate, and reduced production performance, causing serious damage to the poultry breeding industry. Economic losses. Moreover, after being infected with this disease, it will cause the poultry's resistance to decrease, and it is easy to develop secondary coccidiosis, etc., which will aggravate the disease, the treatment effect is not ideal, the mortality rate will increase, sometimes as high as 52%, and the economic loss will be more serious....